OGN
Organon & Co.
NYSE · Healthcare · Drug Manufacturers - General · US
$13.65
+0.07%Price chart
Aug 13Aug 18Aug 21Aug 26Aug 31Sep 3Sep 9Sep 14
Key dataSep 14, 2026
Open$13.64
From 52W high−0.94%
Volume1.25M
Market cap$3.58B
P/E (TTM)17.3x
P/S (TTM)0.6x
Div yield0.59%
Key dataSep 14, 2026
Open
$13.64
From 52W high
−0.94%
Volume
1.25M
Market cap
$3.58B
ValuationView details →
P/E (Fwd)
3.9x
EV/EBITDA
8.4x
P/E (TTM)
17.3x
RSI (14)
42.6
MomentumView details →
1D Return
+0.07%
YTD Return
+90.31%
SummaryUpdated Jun 1, 2026
Organon & Co. (NYSE:OGN) is a global healthcare company that was spun off from Merck & Co. in 2021, focusing on women's health, biosimilars, and established pharmaceutical brands. Founded as an independent entity in 2020 and incorporated in Jersey City, New Jersey, the company went public in May 2021. Organon operates as a specialty pharmaceutical company with a diverse portfolio of prescription therapies sold in the United States and internationally, serving healthcare providers, patients, and health systems worldwide.
Similar companies
Latest newsMore news →
The US FDA accepted for review Organon's supplemental New Drug Application for MIUDELLA, a hormone-free intrauterine device, seeking to extend its approved US use from 3 to 6 years.1d agoSun Pharmaceutical Industries' proposed acquisition of Organon has been approved by shareholders.45d agoShareholders of Organon & Co. approved the merger agreement with Sun Pharmaceutical Holdings USA, Inc. at a virtual special meeting.54d ago